BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/13/2020 3:40:10 AM | Browse: 507 | Download: 1073
 |
Received |
|
2020-08-13 14:54 |
|
Peer-Review Started |
|
2020-08-13 14:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-16 18:20 |
|
Revised |
|
2020-09-29 17:53 |
|
Second Decision |
|
2020-10-16 08:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-10-19 20:16 |
|
Articles in Press |
|
2020-10-19 20:16 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-10-22 22:41 |
|
Typeset the Manuscript |
|
2020-11-12 01:34 |
|
Publish the Manuscript Online |
|
2020-11-13 03:40 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Observational Study |
| Article Title |
Glucagon-like-1 receptor agonists and sodium/glucose cotransporter 2 inhibitors combination—are we exploiting their full potential in a real life setting
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maja Cigrovski Berkovic, Ines Bilic-Curcic, Tomislav Bozek, Davorka Herman Mahecic, Sanja Klobucar Majanovic, Silvija Canecki-Varzic, Jelena Andric, Srecko Marusic and Anna Mrzljak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Anna Mrzljak, MD, PhD, Reader (Associate Professor), Department of Medicine, Merkur University Hospital, School of Medicine, University of Zagreb, Zajčeva 19, Zagreb 10000, Croatia. anna.mrzljak@mef.hr |
| Key Words |
Sodium/glucose cotransporter 2 inhibitors; Glucagon-like-1 receptor agonists; Type 2 diabetes mellitus; Body weight; Glycemic control; Cardiovascular complications |
| Core Tip |
Both glucagon-like-1 receptor agonists and sodium/glucose cotransporter 2 inhibitors when added sequentially to the other or simultaneously decrease the hemoglobin A1c (HbA1c), and reduce the body mass index, but the weight loosing and glucose-lowering potential is not additive in case of their simultaneous use. Half of the patients achieved target HbA1c below 7%, irrespective of treatment group (sequential or simultaneous addition). 5% weight loss was dominantly achieved in the simultaneous therapy group. Composite outcome (reduction of HbA1c below 7% with 5% weight loss) was achieved in 32.3%, while 18.2% of total patients attained composite outcome defined as HbA1c below 7% with 5% weight loss and LDL cholesterol < 2.5 mmol/L. |
| Publish Date |
2020-11-13 03:40 |
| Citation |
Cigrovski Berkovic M, Bilic-Curcic I, Bozek T, Herman Mahecic D, Klobucar Majanovic S, Canecki-Varzic S, Andric J, Marusic S, Mrzljak A. Glucagon-like-1 receptor agonistsGLP-1RA and sodium/glucose cotransporter 2 inhibitors combination—are we exploiting their full potential in a real life setting. World J Diabetes 2020; 11(11): 540-552 |
| URL |
https://www.wjgnet.com/1948-9358/full/v11/i11/540.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v11.i11.540 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
